| Literature DB >> 34354369 |
Huan Yang1,2, Yuan Xu2, Zhijie Li2, Ling Yan2, Jing Wang3, Pu Liao1,2.
Abstract
PURPOSE: To analyze the clinical characteristics of patients with coronavirus disease 19 (COVID-19) in Chongqing, and identify the potential hematological markers for reference. PATIENTS AND METHODS: 78 COVID-19-infected patients in Chongqing were recruited and divided into the non-severe and the severe group. The clinical characteristics and hematological features of the patients of the two groups were compared. Receiver-operating characteristic curves (ROC) were calculated to evaluate the diagnostic performance of potential markers, and the dynamic changes of blood routine analyzing items were compared between the non-severe and severe groups.Entities:
Keywords: COVID-19; lymphocyte; neutrophil; neutrophil-lymphocyte ratio
Year: 2021 PMID: 34354369 PMCID: PMC8331199 DOI: 10.2147/IJGM.S321292
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Clinical Characteristic of COVID-19 Patients in Chongqing
| Total (N=78) | Non-Severe (N=61) | Severe (N=17) | P value | |
|---|---|---|---|---|
| Sex-n. (%) | ||||
| Male | 37 (47.4) | 27 (44.3) | 10 (58.8) | 0.288 |
| Female | 41 (52.6) | 34 (55.7) | 7 (41.2) | |
| Age-year | 45.5 (34.0–55.8) | 43.0 (29.0–50.0) | 59.0 (51.0–68.0) | 0.000 |
| Smoke-no. (%) | 17 (21.8) | 13 (21.3) | 4 (23.5) | 0.845 |
| Alcohol-no. (%) | 21 (26.9) | 14 (23.0) | 7 (41.2) | 0.234 |
| Days from Onset/first nucleic acid positive to Admission | 3.0 (2.0–5.0) | 3.0 (2.0–4.0) | 5.0 (4.0–6.0) | 0.001 |
| Days from Admission to Discharge | 21.5 (14.3–29.0) | 20.0 (13.0–27.0) | 27.0 (20.0–35.0) | 0.019 |
| Days from Onset/first nucleic acid positive to Discharge | 25.0 (17.3–32.8) | 22.0 (17.0–29.0) | 31.0 (26.0–37.0) | 0.001 |
| Acute Phase | 4.0 (3.0–6.0) | 4.0 (3.0–5.0) | 7.0 (5.0–7.0) | 0.000 |
| Progressive Phase | 11.0 (9.0–13.0) | 11.0 (9.0–12.0) | 13.0 (12.0–14.0) | 0.002 |
| Convalescent Phase | 24.5 (17.0–29.0) | 22.0 (16.0–29.0) | 27.0 (25.0–29.0) | 0.021 |
| Symptom-no. (%) | ||||
| Fever | 45 (57.7) | 29 (47.5) | 16 (94.1) | 0.001 |
| Cough | 41 (52.6) | 27 (44.3) | 14 (82.4) | 0.005 |
| Expectoration | 24 (30.8) | 15 (24.6) | 9 (52.9) | 0.025 |
| Pharyngalgia | 11 (14.1) | 10 (16.4) | 1 (5.9) | 0.479 |
| Headache | 15 (19.2) | 7 (11.5) | 8 (47.1) | 0.003 |
| Fatigue | 23 (29.5) | 10 (16.4) | 13 (76.5) | 0.000 |
| Diarrhea | 19 (24.4) | 14 (23.0) | 5 (29.4) | 0.819 |
| Chest tightness | 16 (20.5) | 7 (11.5) | 9 (52.9) | 0.001 |
| Rash | 6 (7.7) | 3 (4.9) | 3 (17.6) | 0.220 |
| Basic diseases-no. (%) | ||||
| Hypertension | 7 (9.0) | 5 (8.2) | 2 (11.8) | 1.000 |
| Diabetes | 5 (6.4) | 0 (0.0) | 5 (29.4) | 0.000 |
| Hematological System diseases | 4 (5.1) | 2 (3.3) | 2 (11.8) | 0.435 |
| Digestive system diseases | 9 (11.5) | 6 (9.8) | 3 (17.6) | 0.644 |
| Cardiovascular system diseases | 3 (3.8) | 1 (1.6) | 2 (11.8) | 0.228 |
| Respiratory system diseases | 1 (1.3) | 0 (0.0) | 1 (5.9) | 0.492 |
| Other Metabolic diseases | 3 (3.8) | 2 (3.3) | 1 (5.9) | 1.000 |
| Comorbidity-no. (%) | ||||
| Respiratory system | 20 (25.6) | 5 (8.2) | 15 (88.2) | 0.000 |
| Digestive system | 11 (4.1) | 7 (11.5) | 4 (23.5) | 0.385 |
| Metabolic diseases | 2 (2.6) | 2 (3.3) | 0 (0.0) | 1.000 |
| Hematological System | 5 (6.4) | 4 (6.6) | 1 (5.9) | 1.000 |
| Immune system | 4 (5.1) | 1 (1.6) | 3 (17.6) | 0.043 |
| Urinary system | 1 (1.3) | 0 (0.0) | 1 (5.9) | 0.492 |
| Neuropsychological system | 2 (2.6) | 1 (1.6) | 1 (5.9) | 0.911 |
| Skin diseases | 3 (3.8) | 0 (0.0) | 3 (17.6) | 0.008 |
| Cardiovascular system | 2 (2.6) | 1 (1.6) | 1 (5.9) | 0.911 |
| Other diseases | 4 (5.1) | 1 (1.6) | 3 (17.6) | 0.043 |
| Chest CT-no. (%) | ||||
| Chest radiographs abnormalities | 59 (75.6) | 42 (68.9) | 17 (100.0) | 0.020 |
The Correlation of Hematological Parameters During the Course of Acute Phase with the Severity of COVID-19 in Chongqing
| Baseline Variables | Total (N=78) | Non-Severe (N=61) | Severe (N=17) | P value |
|---|---|---|---|---|
| WBC (109/L) | 5.3 (4.2–6.7) | 5.4 (4.2–6.8) | 4.9 (3.9–5.9) | 0.189 |
| Neutrophil (109/L) | 3.1 (2.4–4.4) | 3.2 (2.2–4.4) | 3.0 (2.7–4.4) | 0.961 |
| Lymphocyte (109/L) | 1.4 (1.0–2.0) | 1.6 (1.2–2.1) | 1.0 (0.8–1.3) | 0.003 |
| Monocyte (109/L) | 0.4 (0.3–0.5) | 0.4 (0.3–0.5) | 0.3 (0.2–0.5) | 0.059 |
| NLR | 2.2 (1.6–3.3) | 2.1 (1.5–3.0) | 3.3 (2.0–4.3) | 0.028 |
| LMR | 3.7 (2.6–4.8) | 3.8 (2.7–5.4) | 3.7 (2.5–4.3) | 0.374 |
Abbreviations: NLR, neutrophil–lymphocyte ratio; LMR, lymphocyte–monocyte ratio.
Figure 1Dynamic changes of blood analyzing items of COVID-19 between the severe and non-severe groups (A-F). The levels of white blood cell (A), neutrophil (B), lymphocyte (C), monocyte (D), NLR (E), and LMR (F) on three different phases (the acute, progressive, and convalescent-phase) between the severe and non-severe group. *P<0.05, **P<0.01, ***P<0.001.
The Value of Lymphocyte, NLR, Monocyte, LMR, and Neutrophil in the Diagnosis of COVID-19
| Item | Sensitivity (%) | Specificity (%) | Positive Predictive Value (%) | Negative Predictive Value (%) | Cut-off Value |
|---|---|---|---|---|---|
| Lymphocyte | 70.59 | 80.33 | 50.00 | 90.74 | 1.14 |
| NLR | 76.47 | 67.21 | 39.39 | 91.11 | 2.36 |
| Monocyte | 35.29 | 95.08 | 66.67 | 84.06 | 0.25 |
| LMR | 88.24 | 32.79 | 26.79 | 90.91 | 4.75 |
| Neutrophil | 82.35 | 36.07 | 26.42 | 88.00 | 2.64 |
Figure 2The receiver operation curves of hematological parameters for disease severity classification of COVID-19. ROC analysis of lymphocyte, monocyte, NLR, LMR, and neutrophil for discriminating 17 severe cases from 61 non-severe cases.